CalciMedica Inc. (CALC), a clinical-stage biopharmaceutical company, is drawing attention as it develops novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses.
Shares closed Thursday at $3.16, up 0.13 percent, within a day's range of $3.16 to $3.28. The company's 52-week range spans $1.42 to $4.26, with an intraday market capitalization of $45.5 million. Trading volume of 14,098 shares was below the average of 50,179, reflecting a relatively quiet session despite the company's active clinical and corporate updates.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com